Foghorn Therapeutics Inc. reports results for the quarter ended in December - Earnings Summary

Foghorn Therapeutics

10/03/2024 15:41

* Foghorn Therapeutics Inc.  FHTX.OQ  reported a quarterly
adjusted loss of 57 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -69 cents.  The mean expectation of
five analysts for the quarter was for a loss of 76 cents per
share. Wall Street expected results to range from -94 cents
to -63 cents per share.
    * Revenue rose 37.9% to $5.77 million from a year ago;
analysts
expected $4.62 million. 
    * Foghorn Therapeutics Inc.'s reported EPS for the quarter
was a
loss of 57 cents​.
    * The company reported a quarterly loss of $24.11 million.
    * Foghorn Therapeutics Inc. shares had risen by 5.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $14.50 

This summary was machine generated from LSEG data March 10 at
03:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.76          -0.57          Beat
 Sep. 30 2023      -0.75          -0.34          Beat
 Jun. 30 2023      -0.73          -0.70          Beat
 Mar. 31 2023      -0.72          -0.73          Missed